Given the important role of both the in vivo microenvironment and LSC in mediating drug responses, we asked whether targeting ADAM10 may sensitize leukemia cells toward routine chemotherapy used to treat ALL or AML patients. Here, ADAM10 is linked to acute lymphoblastic leukemia.